OS Therapies Inc. held its annual meeting of stockholders on October 21, 2025. Stockholders elected Paul A. Romness, John Ciccio, Avril McKean Dieser, Karim Galzahr, Olivier R. Jarry, and Theodore F. Search to the board of directors. Approval was granted for the issuance of shares of common stock to Ayala Pharmaceuticals, Inc. in connection with an asset purchase transaction. Stockholders also approved an amendment to increase the number of authorized shares of common stock from 50 million to 150 million. An amendment to the company's incentive compensation plan was approved, increasing the number of shares available for issuance under the plan and the maximum number of shares that may be granted to an individual as performance-based compensation. A resolution approving a shareholder rights agreement and authorizing the board of directors to implement it when deemed appropriate was adopted. Additionally, the appointment of MaloneBailey, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-100821), on October 21, 2025, and is solely responsible for the information contained therein.
Comments